Advertisement
Journal of Dermatological Science
Advanced searchSave search
Letter|Articles in Press

Ultraviolet B irradiation leads to the development of experimental bullous pemphigoid targeting BPAG1e

Published:December 05, 2022DOI:https://doi.org/10.1016/j.jdermsci.2022.12.001
Ultraviolet B irradiation leads to the development of experimental bullous pemphigoid targeting BPAG1e
Previous ArticleA cell-based evaluation of human tyrosinase-mediated metabolic activation of leukoderma-inducing phenolic compounds
Next ArticleThe temperature-sensitive receptors TRPV4 and TRPM8 have important roles in the pruritus of rosacea
      Antibodies in the serum of patients with bullous pemphigoid (BP) target two hemidesmosomal proteins, BP180 and BP230/bullous pemphigoid antigen (BPAG)1e [
      • Bernard P.
      • Didierjean L.
      • Denis F.
      • Saurat J.H.
      • Bonnetblanc J.M.
      Heterogeneous bullous pemphigoid antibodies: Detection and characterization by immunoblotting when absent by indirect immunofluorescence.
      J. Invest. Dermatol. 1989; 92: 171-174
      ]. In patients with BP who have only anti-BPAG1e antibodies, the autoantibodies primarily react with the C-terminal domain of BPAG1e (BPAG1e-C) [
      • Hamada T.
      • Nagata Y.
      • Tomita M.
      • Salmhofer W.
      • Hashimoto T.
      Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule.
      Exp. Dermatol. 2001; 10: 256-263
      ,
      • Hayakawa T.
      • Teye K.
      • Hachiya T.
      • Uehara R.
      • Hashiguchi M.
      • Kawakami T.
      • et al.
      Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins.
      Eur. J. Dermatol. 2016; 26: 155-163
      ]. Recently, we found that adoptive transfer of splenocytes from conditional knockout (K5-Cre;Bpag1-/-) mice immunized with murine BPAG1e-C leads to BP-like phenotypes in the recipient immunodeficient mice [
      • Makita E.
      • Matsuzaki Y.
      • Fukui T.
      • Matsui A.
      • Minakawa S.
      • Nakano H.
      • et al.
      Autoantibodies to BPAG1e trigger experimental bullous pemphigoid in mice.
      J. Invest. Dermatol. 2021; 141: 1167-1176. e3
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Dermatological Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Bernard P.
        • Didierjean L.
        • Denis F.
        • Saurat J.H.
        • Bonnetblanc J.M.
        Heterogeneous bullous pemphigoid antibodies: Detection and characterization by immunoblotting when absent by indirect immunofluorescence.
        J. Invest. Dermatol. 1989; 92: 171-174
        View in Article
        • Hamada T.
        • Nagata Y.
        • Tomita M.
        • Salmhofer W.
        • Hashimoto T.
        Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule.
        Exp. Dermatol. 2001; 10: 256-263
        View in Article
        • Hayakawa T.
        • Teye K.
        • Hachiya T.
        • Uehara R.
        • Hashiguchi M.
        • Kawakami T.
        • et al.
        Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins.
        Eur. J. Dermatol. 2016; 26: 155-163
        View in Article
        • Makita E.
        • Matsuzaki Y.
        • Fukui T.
        • Matsui A.
        • Minakawa S.
        • Nakano H.
        • et al.
        Autoantibodies to BPAG1e trigger experimental bullous pemphigoid in mice.
        J. Invest. Dermatol. 2021; 141: 1167-1176. e3
        View in Article
        • Kowalski E.H.
        • Kneibner D.
        • Kridin K.
        • Amber K.T.
        Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid.
        Autoimmun. Rev. 2019; 18: 526-534
        View in Article
        • Narumi H.
        • Nakano H.
        • Matsuzaki Y.
        • Sawamura D.
        • Hanada K.
        Immunohistochemical analysis of in vivo UVB-induced secretion of IL-1α and IL-6 in keratinocytes.
        Mol. Med. Rep. 2011; 4: 611-614
        View in Article
        • Ceryn J.
        • Skibińska M.
        • Barasińska P.
        • Noweta M.
        • Narbutt J.
        • Lesiak A.
        UVB-induced bullous pemphigoid in a patient with psoriasis.
        Post. Dermatol. Alergol. 2022; 39: 228-230
        View in Article
        • Mihara M.
        • Ohsugi Y.
        Possible role of IL-6 in pathogenesis of immune complex-mediated glomerulonephritis in NZB/W FL mice: Induction of IGG class anti-DNA autoantibody production.
        Int. Arch. Allergy Appl. Immunol. 1990; 93: 89-92
        View in Article
        • Schmidt E.
        • Reimer S.
        • Kruse N.
        • Jainta S.
        • Bröcker E.B.
        • Marinkovich M.P.
        • Giudice G.J.
        • Zillikens D.
        Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes.
        J. Invest. Dermatol. 2000; 115: 842-848
        View in Article

      Article info

      Publication history

      Published online: December 05, 2022
      Accepted: December 3, 2022
      Received in revised form: November 14, 2022
      Received: August 2, 2022

      Publication stage

      In Press Journal Pre-Proof

      Identification

      DOI: https://doi.org/10.1016/j.jdermsci.2022.12.001

      Copyright

      © 2022 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX